Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Citric Acid Cycle02:36

The Citric Acid Cycle

162.9K
The citric acid cycle, also known as the Krebs cycle or TCA cycle, consists of several energy-generating reactions that yield one ATP molecule, three NADH molecules, one FADH2 molecule, and two CO2 molecules.
162.9K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

5.1K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Men's health research priorities in men with multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2026
Same author

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.

Drugs·2026
Same author

Use of semaglutide and tirzepatide among people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Tolebrutinib Phase 2b Long-Term Extension Study: Two-Year Safety, MRI, and Clinical Efficacy Outcomes in Patients With Relapsing Multiple Sclerosis Patients.

Neurology open access·2026
Same author

Real world predictors of hypogammaglobulinemia and serious infections in patients receiving ocrelizumab or ofatumumab for the treatment of multiple sclerosis: The REPLACE-MS study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Characterizing Onset Limit and Surgical Outcome Factors in Type II Focal Cortical Dysplasia-Related Epilepsy.

Neurology. Clinical practice·2026
Same journal

Efficacy and Safety of Perampanel in Patients With Brain Tumor-Related Epilepsy: A Systematic Review and Meta-Analysis.

Neurology. Clinical practice·2026
Same journal

Patient-Reported Symptom Burden in Individuals With Parkinson Disease.

Neurology. Clinical practice·2026
Same journal

Global Access to Diagnostic Paraclinical Testing Incorporated in the 2024 Revised McDonald Criteria: Disparities and Opportunity.

Neurology. Clinical practice·2026
Same journal

Clinical Differentiation of Self-Limited Epilepsy With Autonomic Seizures (Panayiotopoulos Syndrome) and Childhood Migraine.

Neurology. Clinical practice·2026
Same journal

The National Association of Epilepsy Centers Accreditation Criteria Should Include Care for People With Functional/Dissociative Seizures.

Neurology. Clinical practice·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K

Dimethyl fumarate for relapsing MS.

Alessandro Serra1, Robert J Fox1

  • 1Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH.

Neurology. Clinical Practice
|February 24, 2018
PubMed
Summary
This summary is machine-generated.

Dimethyl fumarate (DMF) offers potent oral treatment for relapsing-remitting multiple sclerosis (RRMS), significantly reducing relapses and MRI lesions. While generally safe, monitoring for gastrointestinal and skin side effects is recommended.

More Related Videos

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.3K
A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence
08:05

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence

Published on: March 23, 2022

3.1K

Related Experiment Videos

Last Updated: Feb 14, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.3K
A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence
08:05

A Procedure to Study Stress-Induced Relapse of Heroin Seeking after Punishment-Imposed Abstinence

Published on: March 23, 2022

3.1K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disease affecting the central nervous system.
  • Oral therapies offer a convenient administration route for managing RRMS.
  • Dimethyl fumarate (DMF) is an approved oral therapy for RRMS.

Purpose of the Study:

  • To evaluate the efficacy and safety of dimethyl fumarate (DMF) in patients with RRMS.
  • To assess the impact of DMF on relapse rates, MRI lesion activity, and disability progression.
  • To characterize the side effect profile and safety monitoring recommendations for DMF.

Main Methods:

  • Two placebo-controlled, phase III clinical trials were conducted.
  • Patients received twice-daily oral dimethyl fumarate (DMF).
  • Efficacy was measured by annualized relapse rate, new MRI lesions, and disability accumulation. Safety and tolerability were assessed through adverse event reporting and laboratory monitoring.

Main Results:

  • Twice-daily DMF demonstrated a 44%-53% reduction in annualized relapse rate compared to placebo.
  • DMF achieved a 71%-90% reduction in new MRI lesions.
  • One trial showed slowed disability accumulation with DMF, while the other did not. Common side effects included gastrointestinal issues and skin flushing, typically transient. No increased risk of opportunistic infections was observed.

Conclusions:

  • Dimethyl fumarate (DMF) is an effective oral treatment for RRMS, offering significant reductions in relapses and MRI activity.
  • DMF presents a favorable safety and tolerability profile, with manageable side effects and no increased risk of opportunistic infections.
  • DMF is a compelling option for various RRMS treatment scenarios, including first-line therapy, breakthrough disease, and as an alternative for patients intolerant to other treatments or those on natalizumab with JCV antibodies.